Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02767609
Recruitment Status : Completed
First Posted : May 10, 2016
Results First Posted : April 30, 2019
Last Update Posted : April 30, 2019
Sponsor:
Information provided by (Responsible Party):
Brenda Bartnik Olson, PhD, Loma Linda University

Study Type Interventional
Study Design Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Basic Science
Conditions Traumatic Brain Injury
Multiple Sclerosis
Alzheimer's Disease
Tumor
Intervention Device: Magnetic Resonance Imaging
Enrollment 1
Recruitment Details  
Pre-assignment Details  
Arm/Group Title Magentic Resonance Imaging
Hide Arm/Group Description

Magnetic Resonance Imaging.

Magnetic Resonance Imaging: All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.

Period Title: Overall Study
Started 1
Completed 1
Not Completed 0
Arm/Group Title Magentic Resonance Imaging
Hide Arm/Group Description

Magnetic Resonance Imaging.

Magnetic Resonance Imaging: All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.

Overall Number of Baseline Participants 1
Hide Baseline Analysis Population Description
any person between age of 18-90
Age, Continuous  
Mean (Standard Deviation)
Unit of measure:  Years
Number Analyzed 1 participants
32  (0)
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 1 participants
Female 1
Male 0
Race and Ethnicity Not Collected   [1] 
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 0 participants
[1]
Measure Analysis Population Description: Race and Ethnicity were not collected from any participant.
Region of Enrollment  
Measure Type: Number
Unit of measure:  Participants
United States Number Analyzed 1 participants
1
1.Primary Outcome
Title Regional Cerebral Blood Flow Values of the Brain Measured Using Pseudo-continuous Arterial Spin Labeling (pCASL) MRI.
Hide Description The relative cerebral blood flow (CBF) in frontal, parietal, occipital gray matter and white matter regions, basal ganglia, thalami, and cerebellum will be measured using region of interest analysis to determine institutional normative values for healthy subjects.
Time Frame single encounter
Hide Outcome Measure Data
Hide Analysis Population Description
control
Arm/Group Title Magentic Resonance Imaging
Hide Arm/Group Description:

Magnetic Resonance Imaging.

Magnetic Resonance Imaging: All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.

Overall Number of Participants Analyzed 1
Mean (Standard Deviation)
Unit of Measure: ml/100g/min
35.4  (5.7)
Time Frame 1 year
Adverse Event Reporting Description [Not Specified]
 
Arm/Group Title Magentic Resonance Imaging
Hide Arm/Group Description

Magnetic Resonance Imaging.

Magnetic Resonance Imaging: All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.

All-Cause Mortality
Magentic Resonance Imaging
Affected / at Risk (%)
Total   0/1 (0.00%) 
Hide Serious Adverse Events
Magentic Resonance Imaging
Affected / at Risk (%)
Total   0/1 (0.00%) 
Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 0%
Magentic Resonance Imaging
Affected / at Risk (%)
Total   0/1 (0.00%) 
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Layout table for Results Point of Contact information
Name/Title: Brenda Bartnik Olson
Organization: Loma Linda University medical Center
Phone: 909-558-4000 ext 85216
EMail: bbartnik@llu.edu
Layout table for additonal information
Responsible Party: Brenda Bartnik Olson, PhD, Loma Linda University
ClinicalTrials.gov Identifier: NCT02767609    
Other Study ID Numbers: 5140083
First Submitted: May 6, 2016
First Posted: May 10, 2016
Results First Submitted: February 26, 2019
Results First Posted: April 30, 2019
Last Update Posted: April 30, 2019